

CUMULATIVE INDEX 2001

Volume 28

March	CARDIOVASCULAR DISEASE IN THE NEONATE, pages 1-272
June	METABOLIC AND GENETIC SCREENING, pages 273-486
September	UPDATE ON MECHANICAL VENTILATION AND EXOGENOUS SURFACTANT, pages 487-719
December	PRELABOR RUPTURE OF MEMBRANES, pages 721-906

Note: Page numbers of article titles are in **boldface** type.

- Abdomen
distention of, high-frequency ventilation
for, 592, 598
Down syndrome findings in, 309-312
- Abortion, spontaneous
in cystic fibrosis, 387
in increased nuchal transparency
in Down syndrome, 334
with normal karyotype, 341-345
- Abruption, placental, in preterm
premature rupture of membranes, 766
- Accelerated idioventricular rhythm,
neonatal, 200
- Accessory pathways, in heart conduction,
194
- Acid sphingomyelinase deficiency
(Niemann-Pick disease), screening for,
374-375
- Acidosis, in permissive hypercapnia,
526-527
- Acquired immunodeficiency syndrome. *See*
Human immunodeficiency virus
infection.
- Acrania. *See* Neural tube defects.
- Acrocyanosis, versus hypoxemia, 101
- Adenosine, for arrhythmias, 219-220
fetal, 191
neonatal, 202-203
- Adrenal hyperplasia, screening for,
452-453, 456
- AIDS. *See* Human immunodeficiency virus
infection.
- Airflow
in pulmonary graphics, 488-490, 500
sensors for, in patient-triggered ventila-
tion, 535-536
- Airway
elastance and resistance of, in propor-
tional assist ventilation, 567-568
management of, in congenital heart dis-
ease, 104-105
- Alagille syndrome, congenital heart
disease in, 6, 113
- Alcohol, fetal cardiovascular effects of,
55-56
- Alkali infusion, for persistent pulmonary
hypertension, 617
- Alpha-fetoprotein, measurement of
failure to offer, legal aspects of, 465-467
in Down syndrome, 325-326
in neural tube defect screening, 280-282
in second-trimester screening, 292-293,
296-297
versus gestational age and, 280-281
- Alpha stat pH management, in
cardiopulmonary bypass, 161-162
- Alveolar-arterial oxygen difference, in
persistent pulmonary hypertension,
614
- Alveolar ventilation
hypercapnia effects on, 525-526
versus carbon dioxide elimination, in
pulmonary graphics, 499
- Alveoli, volutrauma of, 507-510
- American Academy of Pediatrics-Maternal
and Child Health Bureau Task Force,
newborn screening study of, 427
- Aminoglycosides, ototoxicity of, genetic
screening for, 428-429
- Amiodarone, for arrhythmias, 219
fetal, 191
neonatal, 204

- Amniocentesis
 failure to offer or provide, legal aspects of, 467-469
 fluid leakage after, 851, 881-882
 in intra-amniotic infections, 741-742, 745-746, 839-840
 in maturity testing. *See* Fetus, maturity testing of.
 preterm premature rupture of membranes in, management of, 862-867
 versus vaginal pool fluid collection, in maturity testing, 827
- Amniopatch, in preterm premature rupture of membranes, iatrogenic, 862-867
- Amniostat-FLM test, for maturity, 822, 827-828
- Amniotic fluid
 deficiency of. *See* Oligohydramnios.
 infections of. *See* Intra-amniotic infections.
 infusion of, in oligohydramnios, 756-757, 840-841
 sample collection methods for, in maturity testing, 827
 volume of, after membrane rupture, time to delivery and, 755-756
- Amoxicillin, for preterm premature rupture of membranes, 812
- Amoxicillin-clavulanic acid, for preterm premature rupture of membranes, 812
- Ampicillin, for preterm premature rupture of membranes, 810, 812, 830
- Amrinone, for congestive heart failure, 213-215
- Anaerobic infections, preterm premature rupture of membranes in, 728
- Anemia
 maternal, preterm premature rupture of membranes in, 727
 neonatal, Fanconi's, screening for, 376
 sickle cell. *See* Sickle cell disease and trait.
- Anemometers, as ventilation sensor, 535-536
- Anencephaly. *See* Neural tube defects.
- Anesthesia, in cardiac surgery, in low-birth weight infants, 258-259
- Aneuploidy, screening for, with fetal cells isolated from maternal blood, 359-360
- Angioplasty, for congenital heart disease, 138, 148-152
- Angiotensin-converting enzyme inhibitors, for congestive heart failure, 210-211
- Antiarrhythmic drugs, 215-220
- Antibiotics, for preterm premature rupture of membranes, 762-763
 at 24 to 31 weeks, 843
 before viability, 853, 857-858
 broad-spectrum, 813
 clinical trials of, 809-812
 corticosteroids with, 799-801
 latency to delivery and, 755-756, 809, 812-813, 829-830
 long-term sequelae of, 813-814
 microorganisms involved in, 808
 protocols for, 811-812
 respiratory morbidity and, 829-830
 tocolysis with, 813
- Antiepileptic drugs, fetal cardiovascular effects of, 38-43
- Antitrypsin deficiency, screening for, 454-455
- Aorta, coarctation of, 118-119
 angioplasty for, 151
 fetal circulation in, 15
- Aortic arch, interrupted, 119-120
- Aortic stenosis, 117-118
 balloon valvotomy for, 144-147
- Apnea, in proportional assist ventilation, 572
- Arachidonic acid metabolites
 abnormalities of, persistent pulmonary hypertension in, 611-612
 in preterm premature rupture of membranes, 737
- Arrhythmias, cardiac. *See* Cardiac arrhythmias.
- Arterial switch operation, in transposition of great arteries, 168-173
 in Taussig-Bing anomaly, 170
 results of, 170-173
 with aortic arch obstruction, 170
 with intact ventricular septum in older neonate, 168-170
- Artificial lung expanding compound, 673, 697
- Ashkenazi Jewish population, prenatal screening in, 367-382
 Bloom syndrome, 376
 Canavan's disease, 374
 counseling on, 371, 377-379
 cystic fibrosis, 375-376
 diseases included in, 367-368
 gene frequencies in, 369
 in carriers, 370
 incidence of, 370
 mutations in, 370
 prevention of, 368
 severity categories of, 371-372
 versus other Jewish ethnic groups, 369
 familial dysautonomia, 375
 Fanconi's anemia, 376
 Gaucher's disease, 376-377
 impact of, 368
 in ultrareligious community, 378-379
 mucopolipidosis, 375
 multiption, 378
 Niemann-Pick disease, 374-375
 Tay-Sachs disease, 368, 372-374

- Asphyxia, in preterm premature rupture of membranes, 765-766
- Asplenia-polysplenia syndrome (heterotaxy syndrome), congenital heart disease in, 6-7, 80-81
- Assist-control ventilation
description of, 534, 552
physiologic studies of, 539-540
triggering device for, performance of, 536
versus synchronous intermittent mandatory ventilation, 542-543
- Asthma, surfactant replacement for, 704-705
- Atelectotrauma, volutrauma with, 508-510
- Atrial flutter
fetal, 188
neonatal, 194-197
- Atrial premature beats, neonatal, 206
- Atrial septal defects, 7
- Atrial septoplasty, for congenital heart disease, 139-141
- Atrial septostomy, for congenital heart disease, 137-141
- Atrial trigeminy, fetal, 193
- Atrioventricular block
fetal, 188, 192-193
neonatal, 205-206
- Atrioventricular reciprocating tachycardia
fetal, 188
neonatal, 194-196
- Atrium, catheters in, for postoperative pressure monitoring, 260-261
- Autonomic nervous dysfunction, familial, screening for, 375
- Autotriggering, in patient-triggered ventilation, 532
- Bacterial vaginosis, preterm premature rupture of membranes in, 728
- Balloon procedures, for congenital heart disease, 227
angioplasty, 138, 148-152
atrial septostomy, 137-139
valvotomy, 138, 141-148
- Banana sign, in neural tube defects, 283
- Barometric pressure, preterm premature rupture of membranes and, 729
- Barotrauma, in mechanical ventilation. *See* Volutrauma.
- Beractant, 696
administration routes for, 681
clinical trials of, 675-676
composition of, 672
- Beta-blockers
fetal cardiovascular effects of, 58-59
for arrhythmias
fetal, 191
neonatal, 203-205
for congestive heart failure, 211-212
- Betamethasone, for preterm premature rupture of membranes, 790-791, 798
- Biophysical profile
in intra-amniotic infections, 742-744
in preterm premature rupture of membranes, 765
- Blade septostomy, for congenital heart disease, 139-141
- Blalock-Taussig shunt, thrombosis of, transcatheter removal of, 153
- Bleeding, vaginal, preterm premature rupture of membranes and, 725
- Blood gas, target values for, in high-frequency ventilation, 600
- Blood pressure, proportional assist ventilation effects on, 571-572
- Bloom syndrome, screening for, 376
- Body movement sensors, in patient-triggered ventilation, 535-536
- Bovine-derived surfactants, 672, 696
- Bradycardia
fetal, 192-193
in surfactant administration, 682
neonatal, 205-206
- Brain
abnormal hemodynamic effects on, in congenital heart disease, 236, 238
hemorrhage of
in high-frequency ventilation, 592-596
in permissive hypercapnia, 526
in preterm premature rupture of membranes, 765, 798-799
hypocapnia effects on, 517-521
hypoxic-ischemic damage of, in permissive hypocapnia, 521
imaging of, in congenital heart disease, 111
necrosis of, after cardiac surgery, 241
structural abnormalities of, in congenital heart disease, 235-236
- BRCA1 and BRCA2 genes, mutations of. *See* Hereditary breast and/or ovarian cancer.
- Breast, cancer of, hereditary. *See* Hereditary breast and/or ovarian cancer.
- Breathing
fetal, in preterm premature rupture of membranes, 755
neonatal, control of, proportional assist ventilation effects on, 569-570
synchronous and asynchronous, in pulmonary graphics, 497
- Breech position, in preterm premature rupture of membranes, 766
- Bronchiolitis, surfactant replacement for, 703-704
- Bronchitis, chronic, surfactant replacement for, 704

- Bronchopleural fistula, high-frequency ventilation for, 591-592, 597
- Bronchopulmonary dysplasia, mechanical ventilation and, 523
- Bunnell LifePulse high-frequency jet ventilator, 579-582, 596-597, 600-601
- C-reactive protein, in intra-amniotic infections, 740
- Calf-derived surfactant, 696
- clinical trials of, 675-676
- composition of, 672
- Canavan's disease, screening for, 374
- Cancer
- breast, hereditary. *See* Hereditary breast and/or ovarian cancer.
 - ovarian, hereditary. *See* Hereditary breast and/or ovarian cancer.
- Capillary leak syndrome
- alveolar, volutrauma in, 507
 - in cardiopulmonary bypass, 163-165
- Captopril, for congestive heart failure, 210-211
- Carbamazepine, fetal cardiovascular effects of, 42
- Carbon dioxide
- partial pressure of
 - abnormal. *See* Hypercapnia; Hypocapnia.
 - high-frequency ventilation setting adjustment based on, 602 - status of, in pulmonary graphics, 498-499
- Cardiac arrhythmias, 187-207
- fetal, 187-193
 - bradycardia, 192-193
 - tachycardia, 188-192
 - versus normal rhythm, 187 - neonatal, 193-206
 - bradycardia, 205-206
 - pharmacologic treatment of, 215-220
 - tachycardia, 193-205
- Cardiac catheterization, in persistent pulmonary hypertension, 614
- Cardiac output
- mechanical ventilation effects on, 508
 - proportional assist ventilation effects on, 571-572
- Cardiac surgery
- in congenital heart disease, 159-185
 - absent pulmonary valve, 122-123
 - aortic coarctation, 119
 - complex, long-term developmental outcome of, 235-247
 - complications of, in low-birth weight infants, 250
 - Ebstein's anomaly, 124
 - goals of, in low-birth weight infants, 250-252
 - hypoplastic left heart syndrome, 173-183
 - in low-birth weight infants, 160, 249-264
 - interrupted aortic arch, 119-120
 - long-term developmental outcome of, 235-247
 - in low-birth weight infants, 244
 - intraoperative factors in, 238-239
 - neurologic, 239-244
 - postoperative factors in, 239
 - preoperative factors in, 235-238 - mechanical ventilation in, 256-257
 - necrotizing enterocolitis in, 257-258
 - neurodevelopmental outcome of, in low-birth weight infants, 244
 - nursing care after, 229-231
 - nutrition in, in low-birth weight infants, 255-256
 - outcome of, 160-161
 - palliative, 115-116
 - postoperative care in, in low-birth weight infants, 258-262
 - procedures for, 229-230
 - pulmonic stenosis, 123
 - results of, in low-birth weight infants, 254-255
 - risks of, in low-birth weight infants, 250-252
 - support systems for, 161-165. *See also* Cardiopulmonary bypass.
 - technical issues in, in low-birth weight infants, 252-254
 - tetralogy of Fallot, 121-122
 - thrombosis after, transcatheter procedures for, 153
 - timing of, 159-160
 - in low-birth weight infants, 250-251
 - transposition of great arteries, 166-173 - in fetus, current status of, 22-23
- Cardiomyopathy, fetal, in maternal diabetes mellitus, 33-35
- Cardioplegia, in cardiopulmonary bypass, 162
- Cardiopulmonary bypass, in cardiac surgery, 161-165
- in low-birth weight infants, 253
 - neurodevelopmental effects of, 238-239
 - Norwood procedure, 176-177
- Cardioversion, in arrhythmias, 204
- CATCH 22, congenital heart disease in, 4-6
- Catheterization, cardiac
- for congenital heart disease. *See* Transcatheter procedures, for congenital heart disease.
 - for persistent pulmonary hypertension, 614
- Cells, fetal. *See* Fetal cells.
- Central nervous system, hypocapnia effects on, 517-521

- Cerclage, cervical, preterm premature rupture of membranes after, 877-879
- Cerebral palsy, hypocalcemia causing, 517-519
- Cervix
cerclage of, preterm premature rupture of membranes after, 877-879
conditions of, in preterm premature rupture of membranes, 725-726
- Cesarean delivery, in intra-amniotic infections, 844-845
- Char syndrome, congenital heart disease in, 7
- CHARGE association, congenital heart disease in, 113
- Chemokine(s), in preterm premature rupture of membranes, 738
- Chemokine receptor, mutations of, in HIV infection susceptibility, 432
- Chest
deformity of, in preterm premature rupture of membranes with oligohydramnios, 754-755
Down syndrome findings in, 307-309
radiography of, in heart disease. *See* Radiology, of congenital heart disease.
- Chest wall, distortion of, proportional assist ventilation improvement of, 568-569
- Cheyne-Stokes respiration, in proportional assist ventilation, 570
- Chlamydial infections, preterm premature rupture of membranes in, 728-729
- Chorioamnionitis. *See* Intra-amniotic infections.
- Chorionic villus sampling, fetal anomalies resulting from, legal aspects of, 471-472
- Choroid plexus cysts, in Down syndrome, 306-307
- Chromosomal alterations, congenital heart disease in, 3
- Chronic lung disease, mechanical ventilation in, hypocalcemia and, 523
- Chronic obstructive pulmonary disease, surfactant replacement for, 705
- Circulation
fetal
abnormal, in normal heart structures, 17-18
normal, 12-14
in single ventricle, 130-132
transitional, 130-131
- Circulatory arrest, with deep hypothermia, neurodevelopmental effects of, 239
- Circulatory system, permissive hypercapnia effects on, 527
- Clinodactyly, in Down syndrome, 312-313
- Coil embolization, for congenital heart disease, 138, 152-153
- Colfosceril, 697
administration routes for, 681
composition of, 673
- Collagen, defects of, preterm premature rupture of membranes and, 730-731
- Collectins, in surfactant, 658-659
- Colony-stimulating factors, in preterm premature rupture of membranes, 739
- Compliance, lung, in pulmonary graphics, 494, 496
- Computed tomography, of congenital heart disease, 85
- Concealed accessory pathways, in heart conduction, 194
- Congenital adrenal hyperplasia, screening for, 452-453, 456
- Congenital heart disease, 91-136. *See also specific diseases.*
arrhythmias in. *See* Cardiac arrhythmias.
causes of, 46-47
classification of, 223-224, 250-251
clinical features of, 98
complex, long-term developmental outcome of, 235-247
congestive heart failure in. *See* Congestive heart failure.
counseling in, 23-25
delivery room resuscitation in, 94-98, 104
diagnosis of, 226-227
confirmation of, 109-110
initial, 98-104
nursing, 224-226
radiologic, 71-89
echocardiography in. *See* Echocardiography, in congenital heart disease.
epidemiology of, 2-3
family psychosocial support in, 231-232
flow abnormalities in, in fetus, 14-17
genetic factors in, 3-7, 46-47, 110-113
in fetus. *See* Fetus, congenital heart disease in.
in HIV infection, 52
in preterm premature rupture of membranes, 781
maternal, fetal effects of, 45-50
nursing considerations in, 223-233
physiologic considerations in, 92-93
preoperative evaluation in, 110-115
progression of, in fetus, 18-19
risk factors for, 46-47
stabilization in, 104-108
transport in, 108-109
treatment of
for transport, 104-108
in delivery room, 94-98
in fetus, 22
lesion-specific, 116-133. *See also specific disorders.*
nursing considerations in, 226-227

- Congenital heart disease (*Continued*)
 pharmacologic, 209-222
 preoperative management in, 93
 regional services for, 93
 surgical. *See* Cardiac surgery, in congenital heart disease.
 transcatheter interventions for, 137-157
 versus flow abnormalities in normal heart, 17-18
 versus noncardiac systemic disease, 19-22
 versus normal fetal circulation, 12-14
- Congenital rubella, 50
- Congestive heart failure
 fetal, 189
 neonatal
 incidence of, 11
 nursing care in, 227-228
 signs and symptoms of, 228
 treatment of, 209-215, 228
- Conotruncal anomaly face syndrome,
 congenital heart disease in, 4-6, 112
- Continuous positive airway pressure
 surfactant interactions with, 666
 versus synchronous intermittent mandatory ventilation, 543-544
- Contractures, in preterm premature rupture of membranes, 766-768
- Copper deficiency, preterm premature rupture of membranes in, 724
- Corticosteroids, for preterm premature rupture of membranes, 797-805
 antibiotics with, 799-801
 at 24 to 31 weeks, 843
 before viability, 853
 doses of, 801-802
 efficacy of, 798-799
 fetal maturity testing and, 825-827
 gestational age and, 799
 recommendations for, 802-803
 safety of, 798-799
 tocolysis and, 788, 790-792
- Counseling, in congenital heart disease, prenatal, 23-25
- Coxsackievirus infections, congenital, 51
- Cryoprecipitate, in preterm premature rupture of membrane repair, iatrogenic, 862-867
- Culture, of fetal cells isolated from maternal blood, 357-358
- Cyanosis, in congenital heart disease
 Ebstein's anomaly, 124
 evaluation of, 99-104
- Cyst(s), choroid plexus, in Down syndrome, 306-307
- Cystic adenomatoid malformation,
 treatment of, in fetus, 23
- Cystic fibrosis, 383-393
 clinical features of, 385-386
 description of, 383
 fertility in, 386-388
 genetic considerations in, 383-384
 pathophysiology of, 385-386
 populations susceptible to, 388-389
 pregnancy in, 387-388
 screening for, 375-376, 456
 counseling on, 389-390
 in carriers, 388-390
 prenatal, 390
 surfactant replacement for, 706-707
 treatment of, 386
- Cytokines
 in intra-amniotic infections, 814-815
 in preterm premature rupture of membranes, 738, 763
 corticosteroid effects on, 800
- Cytomegalovirus infections, fetal, heart disease in, 52-53
- Deafness, screening for, 428-429
- Deformations, in preterm premature rupture of membranes, 766-768
- Developmental disorders, after extracorporeal membrane oxygenation, 643-646
- Developmental outcome, of complex congenital heart disease, 235-247
 early postoperative findings in, 240-241
 in low-birth weight infants, 244
 intraoperative factors in, 238-239
 later findings in, 241-244
 postoperative factors in, 239
 preoperative factors in, 235-238
- Dexamethasone, for preterm premature rupture of membranes, 801
 fetal maturity testing and, 825-827
- Diabetes mellitus
 fetal cardiovascular effects of, 32-35
 gestational. *See* Gestational diabetes mellitus.
 preterm premature rupture of membranes in, 727
 screening for, 429-431, 457-458
- Diaphragmatic hernia
 extracorporeal membrane oxygenation for, 639-641
 high-frequency ventilation for, 632
 surfactant replacement for, 703
 treatment of, in fetus, 23
- Diclofenac, fetal cardiovascular effects of, 57-58
- DiGeorge syndrome, congenital heart disease in, 4-6, 112
- Digoxin
 for arrhythmias, 216-217
 fetal, 189, 191
 neonatal, 203

- for congestive heart failure, 228
- DNA, fetal, in maternal blood, 359-361
- DNA analysis, for Tay-Sachs screening, 373
- Dobutamine
 - for congenital heart disease, 107-108
 - for congestive heart failure, 213
- Dopamine
 - for congenital heart disease, 107
 - for congestive heart failure, 212-213
- Double screen, in second trimester, 293
- Down syndrome
 - abdominal findings in, 309-312
 - chest findings in, 307-309
 - congenital heart disease in, 3, 112
 - extremity considerations in, 312-313
 - fetal loss in, 334
 - head and neck findings in, 304-307, 327-328. *See also* Nuchal translucency.
 - incidence of, 303
 - screening for
 - alpha-fetoprotein in, 325-326, 465-467
 - combined, 328
 - dimeric inhibin A in, 296, 326
 - first-trimester, 321-331, 333-352
 - free b-human chorionic gonadotropin in, 324
 - in twin pregnancies, 345, 348
 - integrated test in, 328-329
 - nuchal translucency in, 327-328, 334-341
 - pregnancy-associated plasma protein-A in, 322-323
 - principles of, 276-277
 - Schwangerschaft protein 1 in, 324-325
 - second-trimester, 292, 303-319, 321-322
 - ultrasound in
 - first-trimester, 333-352
 - second-trimester, 303-319
- Drugs. *See also specific drugs.*
 - maternal use of, fetal cardiovascular effects of, 54-59
- Ductus arteriosus
 - constriction of, in fetus, 18
 - patent
 - in Char syndrome, 7
 - maintenance of, 118-119, 227
 - radiography of, 84
 - physiology of, 12-13
 - premature closure of, due to maternal nonsteroidal anti-inflammatory drugs, 57
- Ductus venosus, physiology of, 12-13
- Duodenal atresia, in Down syndrome, 310
- Dysautonomia, familial, screening for, 375
- Ebstein's anomaly, 123-124
- Echocardiography
 - fetal
 - in circulatory abnormalities, 14-18
 - in noncardiac disease, 19-21
 - in congenital heart disease
 - flow abnormalities, 14-17
 - for monitoring progression, 18-19
 - indications for, 11-12
 - maternal issues and. *See* Fetus, congenital heart disease in, maternal issues affecting.
 - in hypertrophic cardiomyopathy, 34-35
 - in congenital heart disease, 94-96, 109
 - Echogenic bowel, in Down syndrome, 310-311
 - ECMO. *See* Extracorporeal membrane oxygenation.
 - Edward's syndrome, congenital heart disease in, 112
 - Elastance, in proportional assist ventilation, 567-568
 - Elastase, in preterm premature rupture of membranes, 739
 - Elastic loading, in mechanical ventilation, 562-564
 - Elastic recoil
 - in preterm premature rupture of membranes, 773-774
 - proportional assist ventilation and, 570-571
 - Ellis-van Creveld syndrome, congenital heart disease in, 113
 - Embolization, coil, for congenital heart disease, 138, 152-153
 - Enalapril, for congestive heart failure, 210-211
 - Encephalocele. *See* Neural tube defects.
 - Endoscopy
 - for preterm premature rupture of membranes, 867-870
 - preterm premature rupture of membranes caused by, 862-867
 - Endotoxin, in intra-amniotic infections, in preterm premature rupture of membranes, 737
 - Endotracheal tube, leak around, in proportional assist ventilation, 573
 - Enterocolitis, necrotizing
 - heart disease with, 257-258
 - in preterm premature rupture of membranes, 765, 810-812
 - Enterovirus infections, congenital, 51
 - Epilepsy, maternal, fetal cardiovascular effects of, 38-43
 - Epinephrine, for congenital heart disease, 107
 - Erythrocyte sedimentation rate, in intra-amniotic infections, 741
 - Erythrocytes, fetal, in maternal blood, for screening tests, 295

- Erythromycin, for preterm premature rupture of membranes, 810, 812, 830
- Estriol, unconjugated, in second-trimester screening, 292-293
- Ethanol, fetal cardiovascular effects of, 55-56
- Ethical issues
in extracorporeal membrane oxygenation trials, 649-650
in screening, 297-298
- Ethosuximide, fetal cardiovascular effects of, 42
- Ethoin, fetal cardiovascular effects of, 42
- Exotoxin, in intra-amniotic infections, in preterm premature rupture of membranes, 737
- Extracorporeal membrane oxygenation, 629-653
alternatives to, 631-638
 high-frequency ventilation, 591, 632-634
 liquid ventilation, 637-638
 nitric oxide, 635-637
 surfactant, 634-635
changing demographics of, 638-642
clinical studies of, 629-631
 ethics of, 649-650
cost-effectiveness of, 647-649
follow-up in, 642-647
for persistent pulmonary hypertension, 620-622
outcome of, 638-642
venovenous, 641
- Extremities, Down syndrome findings in, 312-313
- Familial dysautonomia, screening for, 375
- Familial hypercholesterolemia, screening for, 457
- Fanconi's anemia, screening for, 376
- Fatty acid oxidation defects, screening for, 457
- Feeding problems, after cardiac surgery, 241
- Femur, short, in Down syndrome, 312
- Fence device, for premature rupture of membranes, 756-757
- Fentanyl, for cardiac surgery, in low-birth weight infants, 259
- Fertility, male, in cystic fibrosis, 386-387
- Fetal alcohol syndrome, 55-56
- Fetal cells, in maternal blood, for screening tests, 294-296, 353-365
culture of, 357-358
free DNA derived from, 359-361
future of, 479
isolation of, 354-355
NIFTY study on, 355-356
of aneuploidy, 359-360
of mendelian disorders, 356-357
of preeclampsia, 360-361
polymerase chain reaction in, 356-357
- Fetal hydrops, nonimmune, arrhythmias in, 189
- Fetal inflammatory response, in preterm premature rupture of membranes, 738
- Fetoscopy
for preterm premature rupture of membranes, 867-870
preterm premature rupture of membranes caused by, 862-867
- Fetus
cardiac arrhythmias in. *See* Cardiac arrhythmias, fetal.
circulation of
 abnormal, with normal heart structure, 17-18
 normal, 12-14
congenital heart disease in, 11-29
 counseling in, 23-25
 echocardiography in. *See* Echocardiography, fetal.
 flow abnormalities in, 14-17
 incidence of, 11
 maternal issues affecting, 31-69
 congenital heart disease, 45-50
 diabetes mellitus, 32-35
 drugs, 54-59
 epilepsy, 38-43
 hyperthyroidism, 35-38
 infections, 50-54
 systemic lupus erythematosus, 43-45
 preparation for delivery, 96-97
 treatment of, 22
 versus flow abnormalities in normal heart, 17-18
 versus noncardiac systemic disease, 19-22
 versus normal circulation, 12-14
hypothyroidism in, cardiovascular effects of, 35-38
infections of. *See* Intra-amniotic infections.
maturity testing of
 versus preterm premature rupture of membrane timing, 773
 with preterm premature rupture of membranes, 764, 819-836
 amniotic fluid sample collection methods and, 827
 applicability of, 824-827
 corticosteroid effects on, 825-827
 hazards of, 822-823
 management plans with, 827-834
 predictive value of, 821-822
 racial differences in, 823-824
 results interpretation in, 821

- mortality in, in amniopatch technique, 863-864, 866-867
- Fever, in intra-amniotic infections, 744-745
- Fibrin glue, for preterm premature rupture of membrane repair, 872-873
- Fistulas, respiratory tract, high-frequency ventilation for, 591-592, 597
- Flecainide, for arrhythmias, 191, 218-219
- Fluid therapy
after cardiac surgery, 231
for cardiopulmonary bypass, 162-163
- Fluorescent activated cell sorting, for fetal cell isolation, 354-355
- Folate, for neural tube defect prevention, 280, 291
- Fontan procedure
in hypoplastic left heart syndrome, 177, 182
neurodevelopmental outcome of, 243
- Foramen ovale, physiology of, 12-13
- Foreign bodies, in intracardiac lines, transcatheter removal of, 153
- Functional residual capacity, in mechanical ventilation, optimization of, 510-511
- Galactosemia, screening for, 456
- Gangliosidosis, type 1 (Tay-Sachs disease), screening for, 368, 372-374
- Gardnerella vaginalis*, in intra-amniotic infections, 739
- Gas exchange
hypercapnia effects on, 525-526
surface area for, in preterm premature rupture of membranes, 774-775
- Gastrointestinal system
cystic fibrosis manifestations in, 385
examination of, in congenital heart disease, 114-115
- Gaucher's disease, screening for, 376-377
- Genetic factors, in congenital heart disease, 3-7, 46-47, 110-113
central nervous system abnormalities related to, 236-237
chromosomal, 3
single-gene defects, 7
syndromes, 3-7
- Genital herpes infections, preterm premature rupture of membranes with, 882-883
- Gestational age, determination of, in preterm premature rupture of membranes, 839
- Gestational diabetes mellitus, 407-417
epidemiology of, 407-408
risk factors for, 407-408
screening for
alternatives to, 413-415
benefits of, 410
debate on, 409-411
gestational age for, 409
indications for, 411-412
methods for, 408-409, 412-413
timing of, 408-409, 413
treatment of, 410-411
- Glucose polymer, for glucose tolerance testing, in pregnancy, 414
- Glucose tolerance test, for gestational diabetes mellitus, 408, 412-414
- Glucosidase deficiency (Gaucher's disease), screening for, 377
- Glue, fibrin, for preterm premature rupture of membrane repair, 872-873
- Glycosylated hemoglobin, for glucose tolerance testing, in pregnancy, 414-415
- GM2 gangliosidosis, type 1 (Tay-Sachs disease), screening for, 368, 372-374
- Gonorrhea, preterm premature rupture of membranes in, 729
- Gram stain, in intra-amniotic infections, 741-742
- Graves' disease, maternal, fetal cardiovascular effects of, 35-38
- Growth, in fetal congenital heart disease, 14-15
- Guthrie Inhibition Assay, for phenylketonuria, 470
- Hamartoma, ventricular tachycardia in, 200-201
- Head, Down syndrome findings in, 304-307
- Hearing loss
in permissive hypocapnia, 519-520
screening for, 428-429
- Heart. *See also* Cardiac.
congenital disease of. *See* Congenital heart disease.
defects of
in Down syndrome, 307-309
nuchal transparency in, 343
failure of. *See also* Congestive heart failure.
radiography of
in full-term infant, 81-83
in premature infant, 82-86
fetal, enlargement of, in maternal diabetes mellitus, 33-35
transplantation of, in hypoplastic left heart syndrome, 179, 183
- Heart block
fetal, 188, 192-193
in maternal systemic lupus erythematosus, 43-45
neonatal, 205-206
- Hemi-Fontan procedure, in hypoplastic left heart syndrome, 177, 180-181

- Hemodynamics, proportional assist ventilation effects on, 571-572
- Hemoglobin
glycosylated, for glucose tolerance testing, in pregnancy, 414-415
sickled. *See* Sick cell disease and trait.
- Hemoglobin C disease. *See* Sick cell disease and trait.
- Hemorrhage
intracranial, in high-frequency ventilation, 592-596
intraventricular
in permissive hypercapnia, 526
in preterm premature rupture of membranes, 765
prevention of, antenatal corticosteroids for, 798-799
pulmonary
in surfactant administration, 682-683
surfactant replacement for, 702
- Hemostasis, problems with, in cardiopulmonary bypass, 162
- Hereditary breast and/or ovarian cancer, 395-406
inheritance of, 395-396
management options for, 399, 401-402
risk of
family history of, 397, 399-400
prediction of, versus diagnosis, 402-404
versus mutations, 396-398
screening for, 431
unnecessary interventions in, 402
- Hernia, diaphragmatic. *See* Diaphragmatic hernia.
- Herpes simplex virus infections, genital, preterm premature rupture of membranes with, 882-883
- Heterotaxy syndrome, congenital heart disease in, 6-7, 80-81
- Hexosaminidase A deficiency (Tay-Sachs disease), screening for, 368, 372-374
- HFV. *See* High-frequency ventilation.
- High-frequency ventilation, 579-607
animal studies of, 583-586
blood gas target ranges for, 600
for abdominal distention, 592, 598
for bronchopleural fistula, 591-592, 597
for persistent pulmonary hypertension, 617-618
for respiratory distress syndrome, 585-591
for surfactant deficiency, 583-585
for tracheoesophageal fistula, 591-592, 597
indications for, 596-598
initial settings for, 601
lung inflation target ranges for, 600-601
nitric oxide with, 592
physiology of, 581-583
safety of, 592-596
setting adjustments in, 601-602
strategies for, 599-603
types of, 579-581, 596-598
versus extracorporeal membrane oxygenation, 591, 632-634
volutrauma reduction in, 511-512
weaning from, 598-599, 602-603
- Histiocytoid cardiomyopathy of infancy, 201
- HIV infection. *See* Human immunodeficiency virus infection.
- Holt-Oram syndrome, congenital heart disease in, 4, 113
- Human chorionic gonadotropin measurement
in Down syndrome, 314-315, 324
in second-trimester screening, 292-294, 296-297
- Human Genome Project, screening derived from, 425-434
for breast cancer, 431
for diabetes mellitus, 429-431
for genetic variations in infection susceptibility, 431-432
neonatal, 426-427
for hearing impairment, 428-429
- Human immunodeficiency virus infection
fetal cardiovascular effects of, 52
genetic susceptibility and resistance to, 432
screening for, 275-276, 453-454
- Hyaline membrane disease, prediction of, maturity tests for, 820-821, 828-829
- Hydrocephalus
in Down syndrome, 307
ultrasound screening for, 283
- Hydrops fetalis, arrhythmias in, 189
- Hypercapnia
animal studies of, 522
permissive
gas exchange effects of, 525-526
in preterm infants, 524-525
optimization of, 502-503
pulmonary effects of, 523-524
safety of, 526-528
pulmonary effects of, 521-528
- Hypercholesterolemia, familial, screening for, 457
- Hyperglycemia, maternal, fetal cardiovascular effects of, 32-35
- Hyperoxia test, in congenital heart disease, 100
- Hypertension, pulmonary
persistent. *See* Persistent pulmonary hypertension of newborn.
postoperative, treatment of, 165
- Hyperthyroidism, maternal, fetal cardiovascular effects of, 35-38
- Hypertonia, after cardiac surgery, 241

- Hypertrophic cardiomyopathy, fetal, in maternal diabetes mellitus, 33-35
- Hyperventilation
for persistent pulmonary hypertension, 616-617
central nervous system effects of, 519-520
pulmonary effects of, 524
in proportional assist ventilation, 572-573
- Hypocapnia
central nervous system effects of, 517-521
pulmonary effects of, 521-524
- Hypoperfusion, in congenital heart disease, neurodevelopmental effects of, 236, 238
- Hypoplasia, lung. *See* Lung, hypoplasia of.
- Hypoplastic left heart syndrome
diagnosis of, 173
fetal circulation in, 14-15
radiography of, 81
surgery for, 173-183
anatomic considerations in, 173, 176
goals of, 176
neurodevelopmental outcome of, 243-244
results of, 177, 179, 183
subsequent procedures after, 177, 179-182
technique for, 176-182
transplantation in, 179, 183
- Hypothermia, deep, with circulatory arrest, neurodevelopmental effects of, 239
- Hypothyroidism, screening for, 452, 455
- Hypotonia, after cardiac surgery, 240-241
- Hypoventilation, in proportional assist ventilation, 572
- Hypoxia and hypoxemia
in cardiac surgery, in low-birth weight infants, 259
in congenital heart disease
neurodevelopmental effects of, 236, 238
test for, 226-227
tetralogy of Fallot, 126
treatment of, 126
in preterm premature rupture of membranes, 765-766, 840-841
in surfactant administration, 682
- Ibuprofen, fetal cardiovascular effects of, 57-58
- Immune response, in intra-amniotic infections, 737-738
- Impedance pneumotachography, in ventilation sensing, 536
- Indomethacin, fetal cardiovascular effects of, 57-58
- Infant Star high-frequency jet ventilator, 580-582, 596-597
- Infants of diabetic mothers, congenital heart disease in, 32-35
- Infections
maternal
genital tract, preterm premature rupture of membranes in, 727-729
intra-amniotic. *See* Intra-amniotic infections.
neonatal
in preterm premature rupture of membranes, 762-763
prophylaxis for, in sickle cell disease, 437-438, 440-441
susceptibility to, screening for, 431-432, 453
- Infertility, male, in cystic fibrosis, 386-387
- Inflammatory response, in mechanical ventilation, volutrauma and, 507-508
- Inflation, lung, target values for, in high-frequency ventilation, 600-602
- Informed consent, in genetic counseling, 464-465
- InfraSonics Infant Star high-frequency jet ventilator, 580-582, 596-597
- Inhibin A, dimeric, in prenatal screening, 296, 326
- Inotropic agents, for congenital heart disease, 107-108
- Inspiratory time, in mechanical ventilation, optimization of, pulmonary graphics for, 500-501
- Integrated test, in prenatal screening, 296, 328-329
- Interleukin(s)
in intra-amniotic infections, 741-742, 814-815
in preterm premature rupture of membranes, 738
- Intermittent mandatory ventilation. *See also* Synchronous intermittent mandatory ventilation.
description of, 551
for surfactant deficiency, 583-585
physiologic studies of, 539-540
pressure-preset, 558
- Intestine, anomalies of, in Down syndrome, 309-311
- Intra-amniotic infections, 735-751
amniocentesis in, 741-742, 745-746, 839-840
blood tests for, 740-741
complications of, 736
definition of, 735
detection of, 739-746
fetal, evaluation of, 840
noninvasive testing for, 742-744

Intra-amniotic infections (*Continued*)

- preterm premature rupture of membranes and, 727-729, 744-746, 807-809
 - before viability, 853, 857-858
 - cytokines in, 814-815
 - evidence for, 736-739, 839-840
 - management of, 799-801, 844. *See also* Antibiotics, for preterm premature rupture of membranes.
 - neonatal complications of, 762-763
 - occurring before viability, 850
 - organisms causing, 739, 808
 - pathophysiology of, 736-739
 - risk factors for, 850
 - versus oligohydramnios, 756

Intrauterine infections. *See* Intra-amniotic infections.

Intraventricular hemorrhage

- in permissive hypercapnia, 526
- in preterm premature rupture of membranes, 765
- prevention of, antenatal corticosteroids for, 798-799

Isoproterenol

- for arrhythmias, 206
- for congenital heart disease, 107-108

Isotretinoin, fetal cardiovascular effects of, 56-57

Isoxsuprine, for preterm premature rupture of membranes, 790

JAG1 gene mutations, congenital heart disease in, 6

Jewish population, Ashkenazi. *See* Ashkenazi Jewish population.

Junctional ectopic tachycardia, neonatal, 198

Kidney

- examination of, in congenital heart disease, 111, 114
- pyelectasis of, in Down syndrome, 311

Laser therapy, for preterm premature rupture of membranes, 871-873

Lecithin/sphingomyelin ratio, in maturity testing

- corticosteroid effects on, 825-827
- management plans based on, 827-834
- predictive value of, 821-822
- preterm premature rupture of membranes effects on, 824-825
- racial differences in, 823-824

sample collection method and, 827

Leg-to-foot ratio, in Down syndrome, 312

Legal issues. *See* Medicolegal issues.

Leukocyte elastase, in preterm premature

rupture of membranes, 739

Leukodystrophy, in Canavan's disease,

screening for, 374

Leukomalacia, periventricular, in preterm

premature rupture of membranes, 765

Lidocaine, for arrhythmias

fetal, 191-192

neonatal, 204

LifePulse high-frequency jet ventilator,

579-582, 596-597, 600-601

Lipids, in surfactant, 655-657

Liquid ventilation, versus extracorporeal

membrane oxygenation, 637-638

Lithium, maternal use of, fetal

cardiovascular effects of, 55

Long QT syndrome, neonatal, 201

Low-birth weight infants, cardiac surgery

in, 160, 249-264

complications of, 250

goals of, 250-252

mechanical ventilation in, 256-257

necrotizing enterocolitis in, 257-258

neurodevelopmental outcome of, 244

nutrition in, 255-256

postoperative care in, 258-262

results of, 254-255

risks of, 250-252

technical issues in, 252-254

timing of, 250-251

Lucinactant, 697

Lung. *See also* Respiratory distress

syndrome.

cystic fibrosis manifestations in, 385

elastic recoil of

in preterm premature rupture of membranes, 773-774

proportional assist ventilation and,

570-571

hemorrhage of

in surfactant administration, 682-683

surfactant replacement for, 702

hypoplasia of

high-frequency ventilation for, 598

in circulatory abnormalities, 18

in oligohydramnios, 754, 756-757

in preterm premature rupture of membranes

clinical features of, 771

frequency of, 769

management of, 778-781

mortality in, 776

pathophysiology of, 771-775

inflation of

in mechanical ventilation, optimization of, 510-511

target values for, in high-frequency ventilation, 600-602

- injury of
 in mechanical ventilation. *See* Volu-trauma.
 surfactant replacement for, 700-702
 malformation of, persistent pulmonary hypertension in, 613, 624-625
 maturity of
 acceleration of, in premature rupture of membranes, 824-825
 assessment of. *See* Fetus, maturity testing of.
 transplantation of, surfactant replacement in, 705-706
 volume of. *See also* Tidal volume.
 changes of, injury due to, 508-510
 Lung-to-body-weight ratio, in pulmonary hypoplasia, 771-773
 Lyme disease, fetal effects of, 51-52
 Lymphocytes, fetal, suitability of, for screening tests, 354
 Lysosomal storage disorders, screening for, 375-377
- Magnesium sulfate
 for preterm premature rupture of membranes, 813
 management of, 789-792
 Magnetic activated cell sorting, for fetal cell isolation, 354-355
 MR imaging, of congenital heart disease, 85, 87
 Maladaptation, persistent pulmonary hypertension in, 611-612, 623
 Mastectomy, prophylactic, for breast cancer prevention, 401
 Maternal conditions, fetal cardiovascular effects of. *See* Fetus, congenital heart disease in, maternal issues affecting.
 Maturity testing, fetal. *See* Fetus, maturity testing of.
 Mean airway pressure, versus oxygenation, in pulmonary graphics, 499
 Mechanical ventilation
 assist-control. *See* Assist-control ventilation.
 for persistent pulmonary hypertension, 616-618
 high-frequency. *See* High-frequency ventilation.
 hypocapnia and hypercapnia in, 517-531
 in low-birth weight infants, with heart disease, 256-257
 in preterm premature rupture of membranes, 780-781
 patient-triggered, 533-546
 pressure-regulated volume-controlled, 554-556
 proportional assist, 561-578
 pulmonary graphics for, 487-503
 surfactant interactions with, 663-666, 678
 surfactant treatment with. *See* Surfactant.
 synchrony of, pulmonary graphics and, 501-502
 volume-assured pressure support, 553-554
 volume-controlled, 547-560
 volume-guaranteed pressure-limited, 556-559
 volutrauma in, 505-515, 521
 Meconium aspiration syndrome
 extracorporeal membrane oxygenation for, 639-640
 high-frequency ventilation for, 586, 597-598, 632
 surfactant replacement for, 698-700
 Medicolegal issues, in screening, 463-476
 case histories of claims, 465-472
 damages, 472-475
 emotional stress, 474-475
 genetic counseling guidelines, 464-465
 informed consent, 464-465
 lawsuit awards, 464
 unwanted pregnancy damages, 474
 wrongful birth, 473
 wrongful death, 475
 wrongful life, 473-474
 Membranes, preterm premature rupture of. *See* Preterm premature rupture of membranes.
 Meningocele. *See* Neural tube defects.
 Mephenytoin, fetal cardiovascular effects of, 42
 Mephobarbital, fetal cardiovascular effects of, 42
 Metalloproteinases, excess of, preterm premature rupture of membranes in, 730-731, 738-739
 Methosuximide, fetal cardiovascular effects of, 42
 Milrinone, for congestive heart failure, 213-215
 Misoprostol, for labor induction, in preterm premature rupture of membranes, 842
 Mitral valve, stenosis of, balloon valvotomy for, 147
 Monosomy X, congenital heart disease in, 112
 Mortality
 fetal
 in amniopatch technique, 863-864, 866-867
 in preterm premature rupture of membranes, corticosteroids and, 798
 neonatal, in preterm premature rupture of membranes, 754, 775-777, 798, 851

- Mucopolidosis IV, screening for, 375
- Multifetal pregnancy, preterm premature rupture of membranes in, 726
- Multifocal atrial tachycardia, neonatal, 198
- Mumps, embryopathy in, controversy over, 50-51
- Muscle tone, abnormal, after cardiac surgery, 240-241
- Mycoplasmal infections
intra-amniotic, 739
preterm premature rupture of membranes in, 728-729
- Myelomeningocele. *See* Neural tube defects.
- Myocardium, tumors of, ventricular tachycardia in, 200-201
- Narrow complex tachycardia, neonatal, 196-197
- National Institutes of Child Health and Development Fetal Cell Isolation Study, 355-356
- Neck, Down syndrome findings in, 304-307, 327-328. *See also* Nuchal translucency.
- Necrotizing enterocolitis
heart disease with, 257-258
in preterm premature rupture of membranes, 765, 810-812
- Neonatal lupus syndrome, 43-45
- Neonates, screening of, 449-461
cost considerations in, 451
for adrenal hyperplasia, 452-453, 456
for antitrypsin deficiency, 454-455
for cystic fibrosis, 456
for diabetes mellitus, 457-458
for familial hypercholesterolemia, 457
for fatty acid oxidation defects, 457
for galactosemia, 456
for hearing impairment, 428-429
for HIV infection, 453-454
for hypothyroidism, 452, 455
for phenylketonuria, 419-424, 455
for sickle cell disease, 437-444
for toxoplasmosis, 453
for tyrosinemia, 456-457
future of, 455-458, 477-480
goals of, 451
guidelines for, 450-451
history of, 449-450
methods for, 450
nationwide disparities in, 426-427
- Neural tube defects, 279-287
causes of, 280
embryology of, 279
incidence of, 280, 290-291
nuchal transparency in, 343
screening for
biochemical, 280-282, 290-292
failure to detect in, legal aspects of, 469-471
history of, 280
second-trimester, 290-292
ultrasound, 282-286
types of, 279
- Neurologic disorders
after cardiac surgery, for congenital heart disease. *See* Developmental outcome, of complex congenital heart disease.
after extracorporeal membrane oxygenation, 643-646
- Niemann-Pick disease, screening for, 374-375
- NIFTY (National Institutes of Child Health and Development Fetal Cell Isolation Study), 355-356
- Nitric oxide
for persistent pulmonary hypertension, 618-621, 635-637, 647
for pulmonary hypertension, postoperative, 165
versus extracorporeal membrane oxygenation, 642
with high-frequency ventilation, 592
- Nonimmune fetal hydrops, arrhythmias in, 189
- Nonreactive nonstress test, in intra-amniotic infections, 742-744
- Nonsteroidal anti-inflammatory drugs, fetal cardiovascular effects of, 57-58
- Noonan syndrome, congenital heart disease in, 113
- Norwood procedure
for aortic valve stenosis, 145
for hypoplastic left heart syndrome, 173-183
anatomic considerations in, 173, 176
goals of, 176
results of, 177, 179, 183
subsequent procedures after, 177, 179-182
technique for, 176-182
- Nuchal skinfold thickness, in Down syndrome, 304-306
- Nuchal translucency
in Down syndrome, 327-328, 334-341
in genetic syndromes, 343-347
in heart defects, 343
in skeletal dysplasias, 343-347
with normal karyotype, 341-345
- Nursing considerations, in congenital heart disease, 223-233
diagnosis in, 226-227
disease classification and, 223-224
evaluation in, 224-226
family psychosocial support in, 231-232
postoperative, 229-231
treatment of, 226-227

- with congestive heart failure, 227-228
- Nutrition
 - in low-birth weight infants, with heart disease, 255-256
 - maternal, preterm premature rupture of membranes and, 723-725
 - neonatal, after cardiac surgery, 231
- Oligohydramnios, 753-759
 - causes of, 755
 - fetal anomalies in, 753-755
 - preterm premature rupture of membranes with
 - deformities in, 754-755, 766-768
 - fetal distress in, 840-841
 - latency to delivery and, 755-756
 - management of, 756-757
 - versus intra-amniotic infection, 756
- Oncocytic cardiomyopathy of infancy, 201
- Oophorectomy, prophylactic, in ovarian cancer prevention, 402
- Oral contraceptives, for ovarian cancer prevention, 402
- Otitis media, surfactant replacement for, 707
- Ovary, cancer of, hereditary. *See* Hereditary breast and/or ovarian cancer.
- Oxygen status
 - in mechanical ventilation, optimization of, 502
 - in pulmonary graphics, 497-499, 502
- Oxygen therapy, for congenital heart disease, 104-105, 122
- Oxygenation index, in persistent pulmonary hypertension, 614-615
- Oxytocin, for labor induction, in preterm premature rupture of membranes, 842
- Pacemaker
 - for arrhythmias, 204, 206
 - temporary, after cardiac surgery, 261-262
- Pain control, after cardiac surgery, in low-birth weight infants, 258-259
- Pancreas, cystic fibrosis manifestations in, 385
- Parvovirus B19 infections, fetal, 53-54
- Patau's syndrome, congenital heart disease in, 112
- Patent ductus arteriosus. *See* Ductus arteriosus, patent.
- Patient-triggered ventilation, 533-546
 - assist-control, 542-543
 - continuous positive airway pressure, 543-544
 - devices for, 535-539
 - modes of, 534
 - nasopharyngeal, 543-544
 - physiologic studies of, 539-540
 - synchronous intermittent mandatory, 534, 542-544
 - ventilator performance during, 538-539
 - versus conventional mechanical ventilation, 540-542
 - versus pressure-preset intermittent mandatory ventilation, 558
- Peak end-expiratory pressure, optimization of, pulmonary graphics for, 500
- PEEP. *See* Positive end-expiratory pressure.
- Periventricular leukomalacia
 - in high-frequency ventilation, 592-596
 - in hypocapnia, 517-519
 - in preterm premature rupture of membranes, 765
- Persistent pulmonary hypertension of newborn, 609-627
 - diagnosis of, 613-615
 - epidemiology of, 609-610
 - pathophysiology of, 610-613, 622-625
 - treatment of, 615-625
 - alkali in, 617
 - extracorporeal membrane oxygenation in, 620-622, 635-637, 639-640
 - high-frequency ventilation in, 597, 632
 - hyperventilation in, 616-617
 - nitric oxide in, 618-621, 635-637
 - permissive hypercapnia in, 523-524
 - permissive hypocapnia in, 519-520
 - related to pathophysiology, 622-625
 - surfactant in, 617-618
 - vasodilators in, 618
 - ventilation in, 616-618
- pH management, in cardiopulmonary bypass, 161-162
- Phenobarbital, fetal cardiovascular effects of, 42
- Phensuximide, fetal cardiovascular effects of, 42
- Phenylalanine hydroxylase deficiency of. *See* Phenylketonuria.
- Phenylketonuria
 - blood levels in, 420-421
 - screening for, 419-424, 455
 - genetic implications of, 419-420
 - maternal, 421-423
 - neonatal, 419-424, 455
 - prenatal, 421-423
 - variable phenylalanine levels in, 421
- Phenytoin, fetal cardiovascular effects of, 42
- Phosphatidylglycerol, in maturity testing, predictive value of, 822
- Phosphodiesterase inhibitors, in congestive heart failure, 213-215
- Phospholipase, in preterm premature rupture of membranes, 737

- Phospholipids, in surfactant, 655-656
- Placenta, abruptio of, in preterm
premature rupture of membranes, 766
- Platelets, in preterm premature rupture of
membrane repair, iatrogenic, 862-867
- Pneumatic capsule, as ventilation sensor,
535-536
- Pneumonia
extracorporeal membrane oxygenation
for, 639-640
high-frequency ventilation for, 597, 632
in preterm premature rupture of mem-
branes, 769
surfactant replacement for, 702-703
- Polymerase chain reaction, for mendelian
disorder detection, in fetal cells,
356-357
- Poractant, 696
administration routes for, 681
composition of, 672
- Positive end-expiratory pressure
for atelectotrauma prevention, 509
surfactant interactions with, 664-666
- Postgenomic medicine. *See* Human
Genome Project, screening derived
from.
- Potter sequence, in oligohydramnios,
753-754
- Predictive value, of screening tests,
274-277
- Preeclampsia, fetal cell traffic and free fetal
DNA in, 360-361
- Pregnancy
disorders in, cardiovascular effects of.
See Fetus, congenital heart disease
in, maternal issues affecting,
in cystic fibrosis, 387-388
screening in. *See also* Prenatal screening,
for diabetes mellitus. *See* Gestational
diabetes mellitus.
for sickle cell disease, 444-446
- Pregnancy-associated plasma protein-A,
measurement of, in Down syndrome,
322-323
- Premature atrial contractions, fetal, 193
- Premature infants
heart failure in, radiography of, 82-86
low-birth weight. *See* Low-birth weight
infants.
permissive hypercapnia in, 524-525
preterm premature rupture of mem-
branes and, 763-765, 776, 795
before viability, 843-844, 849-860
- Premature rupture of membranes, preterm.
See Preterm premature rupture of
membranes.
- Prenatal screening
double screen in, 293
fetal components in maternal blood for,
294-296, 353-365
- first-trimester
for Down syndrome, 321-331
ultrasound in, 333-352
for Down syndrome. *See* Down syn-
drome, screening for.
for neural tube defects. *See* Neural tube
defects.
future of, 479
of Ashkenazi Jewish population, 367-382
second-trimester, 289-301
triple screen in, 292-296
- Pressure
barometric, preterm premature rupture
of membranes and, 729
in pulmonary graphics, 488-490, 500
Pressure-airflow relationships, in
pulmonary graphics, 491, 494-495
Pressure-regulated volume-controlled
ventilation, 554-556
Pressure-volume relationships, in
pulmonary graphics, 491-493
Preterm premature rupture of membranes,
721-734
after cervical cerclage, 877-879
barometric pressure and, 729
before viability, 849-860
definition of, 849-850
diagnosis of, 850
etiology of, 850-851
management of, 843-844, 855, 857-858
natural history of, 851-852
outcome of, 851-856
recurrence risk for, 858
case studies of, endoscopic assessment
in, 868-870
causes of, 722-729, 808
cervical parameters in, 725-726
collagen content and metabolism and,
729-731
definition of, 721
delivery room care in, 779-781
diagnosis of, 838-839
endoscopic assessment of, 867-870
epidemiology of, 721, 753, 807
genital tract infection and, 727-729
history of, 726-727
iatrogenic, management of, 862-867
in amniocentesis, management of, 881-
882
in multifetal pregnancy, 726
intra-amniotic infection in. *See* Intra-am-
niotic infections.
latency to delivery and, 808, 814
antibiotic effects on, 755-756, 809-813,
829-830
cervical cerclage and, 877-879
corticosteroid effects on, 802-803
gestational age and, 839
in oligohydramnios, 755-756
in tocolysis, 789-795

- with resealing, 882
- management of, 776-777, 787, **837-847**, **861-875**
 - after amniocentesis, 881-882
 - after cervical cerclage, 877-879
 - amniopatch in, 862-867
 - antibiotics in. *See* Antibiotics, for preterm premature rupture of membranes.
 - at 24 to 31 weeks, 843
 - at 32 to 34 weeks, 842-843
 - at 23 weeks or less, 843-844
 - controversies in, 877-884
 - corticosteroids in. *See* Corticosteroids, for preterm premature rupture of membranes.
 - evaluation for, 838-841
 - fetal distress evaluation in, 840-841
 - fibrin glue in, 872-873
 - gestational age determination in, 839
 - home care in, 880-881
 - iatrogenic, 862-867
 - infection evaluation in, 839-840
 - inpatient versus home, 880-881
 - labor detection in, 839
 - labor induction in, 841-842
 - laser welding in, 871-873
 - maturity testing guidelines for, 827-834
 - surgical, 871-873
 - term and near term, 841-842
 - tocolysis in. *See* Tocolysis.
 - with genital herpes, 882-883
 - with intra-amniotic infection, 844-845
 - with oligohydramnios, 756-757
 - with resealing, 879-880
- maturity testing with, 764, 773, **819-836**
- mechanisms of, 729-731
- mortality in, fetal, 754, 775-777, 798
- neonatal complications of, **761-785**
 - asphyxia, 765-766
 - contractures, 766-768
 - deformations, 766-768
 - developmental, 775-777
 - infection, 762-763
 - intraventricular hemorrhage, 765
 - management of, 778-781
 - mortality, 754, 775-777, 798, 851
 - necrotizing enterocolitis, 765, 810-812
 - prematurity, 763-765
 - pulmonary hypoplasia, 754, 756-757, 769-775
- nutritional factors in, 723-725
- oligohydramnios with, **753-759**, 766-768, 840-841
- pre-existing medical conditions and, 727
- racial factors in, 722
- resealing in, 879-880
- sexual activity and, 723
- smoking and, 722-723
- socioeconomic factors in, 722
- vaginal bleeding and, 725
- with genital herpes, 882-883
- Primidone, fetal cardiovascular effects of, 42
- Procainamide, for arrhythmias, 217-218
 - fetal, 191
 - neonatal, 203-204
- Propafenone, for arrhythmias, 218
- Proportional assist ventilation, **561-578**
 - concept of, 562-564
 - description of, 534
 - respiratory mechanical unloading with, 562-564
 - breathing control and, 569-570
 - chest wall distortion and, 568-569
 - clinical applications of, 573-576
 - hemodynamic effects of, 571-572
 - lung elastic recoil overcompensation and, 570-571
 - objectives of, 564-566
 - pitfalls in, 572-573
 - pulmonary resistance and, 570-571
 - respiratory mechanical effects of, 567-568
 - results of, 574-576
 - selection of assist type and degree for, 573, 575
 - sensor malfunction in, 573
 - side effects of, 572-573
 - terminology of, 564-566
 - tidal volume regional distribution in, 568-569
- Propranolol, for congestive heart failure, 212
- Prostaglandins
 - abnormalities of, persistent pulmonary hypertension in, 611-612
 - for congenital heart disease, 105-107
 - for ductus arteriosus maintenance, 118-119, 227
 - for labor induction, in preterm premature rupture of membranes, 842
 - for pulmonary stenosis, 142-143
 - in intra-amniotic infections, in preterm premature rupture of membranes, 737
 - inhibitors of, fetal cardiovascular effects of, 57-58
- Proteins, hydrophobic, in surfactant, 657-659
- Psychosocial support, for family, in congenital heart disease, 231-232
- Public policy, on screening, 297-298
- Pulmonary air leak syndrome, extracorporeal membrane oxygenation for, 639-640
- Pulmonary arteries
 - abnormalities of, persistent pulmonary hypertension in, 611-613, 623-624

Pulmonary arteries (*Continued*)

stenosis of, angioplasty for, 148-151

Pulmonary blood flow

evaluation of, of congenital heart disease, 77-79

excessive, in single ventricle, 131-132

inadequate, in single ventricle, 131

Pulmonary circulation, surfactant effects on, 673

Pulmonary disease, maternal, preterm premature rupture of membranes in, 727

Pulmonary edema, surfactant replacement for, 700-702

Pulmonary graphics, 487-503

airflow in, 490

carbon dioxide status in, 498-499

description of, 487

driving pressure in, 489-490

in bedside ventilation management, 499-503

oxygenation status in, 497-499

pressure-airflow relationships in, 491, 494-495

pressure-volume relationships in, 491-493

pulmonary mechanics in, 494, 496-497

respiration signals in, 488-489

synchronous and asynchronous breathing in, 497

tidal flow-volume relationships in, 490-491

tidal volume in, 489

Pulmonary hypertension

persistent. *See* Persistent pulmonary hypertension of newborn.

postoperative, treatment of, 165

Pulmonary hypoplasia. *See* Lung, hypoplasia of.

Pulmonary pressure, measurement of, in persistent pulmonary hypertension, 614

Pulmonary resistance, proportional assist ventilation and, 570-571

Pulmonary valve

absence of, in tetralogy of Fallot, 122-123

stenosis of, 123, 141-144

Pulmonary veins

anomalous connections of, 81-82, 127-128

stenosis of, angioplasty for, 151-152

Purkinje cell tumors, 201

Pylectasis, in Down syndrome, 311

Quinidine, for cardiac arrhythmias, fetal, 191

Racial factors

in fetal maturity testing, 823-824

in preterm premature rupture of membranes, 722

Radial alveolar count, in pulmonary hypoplasia, 773

Radiology, of congenital heart disease, 71-89

heart failure, 81-86

heterotaxy, 80-81

interpretation of, 72-76

new developments in, 85, 87

pulmonary blood flow studies in, 77-79

versus normal findings, 77

Resistance, in proportional assist ventilation, 568

Resistive loading, in mechanical ventilation, 563-564

Resistive properties, in pulmonary graphics, 496-497

Respiratory cycles, 488-489

Respiratory distress syndrome

in preterm premature rupture of membranes, 764-765, 810-811

pathophysiology of, 506-507

prediction of, maturity testing for. *See* Fetus, maturity testing of.

prevention of, antenatal corticosteroids for, 798-799

treatment of

extracorporeal membrane oxygenation in, 634-635, 639-640

high-frequency ventilation in, 587-591, 632

permissive hypercapnia in, 522, 524-525

surfactant in. *See* Surfactant, replacement of.

versus hyaline membrane disease, 820

Respiratory mechanical unloading. *See* Proportional assist ventilation.

Respiratory syncytial virus pneumonia, surfactant replacement for, 703-704

Restrictive pulmonary artery disease with flow limitation, 613

Resuscitation

in congenital heart disease, 94-98, 104

in preterm premature rupture of membranes, 779-780

Retinol and derivatives, fetal

cardiovascular effects of, 56-57

Ritodrine

fetal cardiovascular effects of, 58-59

for preterm premature rupture of membranes, 788-789, 792, 813

Röhrer equation, for respiratory function, 489

Rubella, congenital, 50

- Rupture of membranes, preterm
 premature, preterm premature rupture
 of. *See* Preterm premature rupture of
 membranes.
- Sandal gap toe, in Down syndrome, 313
- Schwangerschaft protein 1, in Down
 syndrome, 324-325
- Scimitar syndrome, radiography of, 79
- Screening
 definition of, 274
 ethical issues in, 297-298
 for Bloom syndrome, 376
 for Canavan's disease, 374
 for congenital adrenal hyperplasia, 452-
 453, 456
 for cystic fibrosis, 375-376
 for diabetes mellitus, 419-431, 457-458.
See also Gestational diabetes melli-
 tus.
 for Down syndrome. *See* Down syn-
 drome.
 for familial dysautonomia, 375
 for familial hypercholesterolemia, 457
 for Fanconi's anemia, 376
 for fatty acid oxidation defects, 457
 for galactosemia, 456
 for Gaucher's disease, 376-377
 for hearing impairment, 428-429
 for hereditary breast and ovarian cancer.
See Hereditary breast and/or ovar-
 ian cancer.
 for HIV infection, 453-454
 for hypothyroidism, 452, 455
 for infection genetic susceptibility, 431-
 432
 for mucopolidosis, 375
 for neural tube defects. *See* Neural tube
 defects.
 for Niemann-Pick disease, 374-375
 for phenylketonuria. *See* Phenylketonu-
 ria.
 for sickle cell-related conditions, 435-448
 for Tay-Sachs disease, 368, 372-374
 for tyrosinemia, 456-457
 future of, 477-480
 Human Genome Project impact on, 425-
 434
 integrated test in, 296, 328-329
 medicolegal issues in, 463-476
 neonatal. *See* Neonates, screening of.
 parental. *See also* Pregnancy, screening
 in.
 for cancer, breast and ovarian, 395-
 406, 431
 for cystic fibrosis, 383-393
 predictive value of, 274-277
 prenatal. *See* Prenatal screening.
- principles of, 273-278
 public policy on, 297-298
 sensitivity of, 274-277
 specificity of, 274-277
 treatments initiated after, 478
 versus diagnostic tests, 273-274
- Sedation, after cardiac surgery, in
 low-birth weight infants, 258-259
- Seizures
 after cardiac surgery, 240
 maternal, fetal cardiovascular effects of,
 38-43
- Sensitivity, of screening tests, 274-277
- SensorMedics high-frequency jet ventilator,
 580-582, 596-597, 600-601
- Sepsis
 extracorporeal membrane oxygenation
 for, 639-640
 in preterm premature rupture of mem-
 branes, 762-763, 798
 antibiotic effects on, 810-813
 corticosteroid effects on, 798, 800-801
 prevention of, antenatal corticosteroids
 and, 798, 800-801
 surfactant replacement for, 702-703
- Septoplasty, atrial, for congenital heart
 disease, 139-141
- Septostomy
 atrial, for congenital heart disease, 137-
 141
 blade, for congenital heart disease, 139-
 141
- Sexual activity, preterm premature rupture
 of membranes and, 723
- Shone's syndrome, single ventricle in,
 128-129
- Shunts
 in persistent pulmonary hypertension,
 613-614
 left-to-right, 132-133
- Sickle cell disease and trait, 435-448
 epidemiology of, 435
 infection prophylaxis in, 437-438, 440-
 441
 screening for, 437-444
 counseling on, 442-446
 follow-up activities in, 440-441
 historical aspects of, 436-437
 in anemia, 447
 in Medicaid beneficiaries, 446
 in neonates, 437-444
 in parents, 441-442
 in pregnancy, 444-446
 methods for, 438
 preoperative, 447
 repeat testing in, 438, 440-441
 results interpretation in, 439
 terminology of, 435-436
- Single-ventricle disorders, 128-132, 243
- Situs ambiguous (heterotaxy syndrome),
 congenital heart disease in, 6-7, 80-81

- Skeletal dysplasias, nuchal translucency in, 343-347
- Skull, defects of. *See* Neural tube defects.
- Smoking, preterm premature rupture of membranes and, 722-723
- Socioeconomic factors, in preterm premature rupture of membranes, 722
- Sodium bicarbonate, for persistent pulmonary hypertension, 617
- Sotalol, for arrhythmias, fetal, 191
- Specificity, of screening tests, 274-277
- Sphingomyelinase deficiency (Niemann-Pick disease), screening for, 374-375
- Spina bifida. *See* Neural tube defects.
- SPs (surfactant proteins), in surfactant, 657-659
- Streptococcus agalactiae*, in intra-amniotic infections, 739
- Stress reduction, in cardiac surgery, in low-birth weight infants, 258-259
- Stress tests, fetal
in intra-amniotic infections, 742-744
in preterm premature rupture of membranes, 840-841
- Supraventricular tachycardia
fetal, 188-189, 191
neonatal, 194-205, 215-220
- Surfactant, **655-669**
components of, 655-659, 671-672
collectins, 658-659
hydrophobic proteins, 657-658
lipids, 655-657
deficiency of
high-frequency ventilation for, 583-585
mechanical ventilation in, 663-666
replacement effects on, 662-663
disruption of, volutrauma in, 507
interactions of, with mechanical ventilation, 663-666
lung mechanics and, 662-663
metabolism of, 659-662
proteins of, 657-659
replacement of, **671-694, 695-711**
administration methods for, 680-682
adverse effects of, 682-683
clinical trials of, 674-682
composition of, 671-672
early, 678-679
economic aspects of, 683-684
for acute lung injury, 700-702
for asthma, 704-705
for bronchiolitis, 703-704
for chronic bronchitis, 704
for chronic obstructive pulmonary disease, 705
for cystic fibrosis, 706-707
for diaphragmatic hernia, 703
for lung transplantation, 705-706
for meconium aspiration syndrome, 698-700
for otitis media, 707
for persistent pulmonary hypertension, 617-618
for pneumonia, 702-703
for pulmonary hemorrhage, 702
for respiratory distress syndrome, 634-635, 700-702
for respiratory syncytial virus pneumonia, 703-704
for sepsis, 702-703
indications for, 696-697
late, 678-679
long-term outcomes of, 685-686
lung mechanics in, 662-663
natural, 695-696
types of, 675-676
versus synthetic, 674-675
prophylactic, 511, 676-678, 685-686
pulmonary circulation effects of, 673
pulmonary effects of, 673
radiographic changes in, 673
repeated administration of, 679-680
rescue, 676-677, 685-686
response to, 684
synthetic, 674-675, 695-696
types of, 672-673
versus no therapy, 674
versus placebo, 674
- Surfactant TA, 672, 696
- Sweat, salt content of, in cystic fibrosis, 385-386
- Synchronous intermittent mandatory ventilation
description of, 534, 551-552
nasopharyngeal, 543-544
physiologic studies of, 539-540
versus assist-control ventilation, 542-543
versus continuous positive airway pressure, 543-544
- Syphilis, congenital, cardiovascular effects of, 53
- Systemic inflammatory response, in mechanical ventilation, 508
- Systemic lupus erythematosus, fetal cardiovascular effects of, 43-45
- Tachycardia. *See also* Supraventricular tachycardia; Ventricular tachycardia.
fetal, 188-192
in hyperthyroidism, 38
neonatal, 193-205
- Tamoxifen, for breast cancer prevention, 401
- Tandem mass spectrometry, for screening, 450, 470
- Tay-Sachs disease, screening for, 368, 372-374
- Teratogens, congenital heart disease due to, 2. *See also* Fetus, congenital heart disease in, maternal issues affecting.

- Terbutaline
fetal cardiovascular effects of, 58-59
for preterm premature rupture of membranes, 789-790, 792
- Tetralogy of Fallot, 121-122
fetal circulation in, 15, 17
spells in, management of, 122
with absent pulmonary valve, 122-123
- Thalassemia. *See* Sickle cell disease and trait.
- Thrombocytopenia-absent radius syndrome, congenital heart disease in, 113
- Thrombosis, postoperative, transcatheter procedures for, 153
- Thyroid hormones, for hypothyroidism screening, 452
- Ticarcillin-clavulanic acid, for preterm premature rupture of membranes, 812
- Tidal flow-volume relationships, in pulmonary graphics, 490-491
- Tidal volume
in mechanical ventilation
for functional residual capacity optimization, 510-511
optimization of, 502, 511-512
in pulmonary graphics, 489, 502
regional distribution of, proportional assisted ventilation improvement of, 568-569
- Tocolysis
fetal cardiovascular effects of, 58-59
for preterm premature rupture of membranes, 787-796, 813
at 24 to 31 weeks, 843
before viability, 853, 855
future of, 794-795
prophylactic, 788-789, 791-793
therapeutic, 790-793
- Toe(s), anomalies of, in Down syndrome, 313
- Tolazoline, for persistent pulmonary hypertension, 618
- Total anomalous pulmonary venous return, 81-82, 127-128
- Toxins, in intra-amniotic infections, in preterm premature rupture of membranes, 737
- Toxoplasmosis
congenital, heart disease in, 53
screening for, 453
- Tracheoesophageal fistula, high-frequency ventilation for, 591-592, 597
- Transcatheter procedures, for congenital heart disease, 109-110, 137-157, 227
angioplasty, 138, 148-152
atrial septoplasty, 139-141
atrial septostomy, 137-141
coil embolization, 138, 152-153
foreign body retrieval, 153
thrombosis removal, 153
valvotomy, 138, 141-148
- Transplantation
heart, in hypoplastic left heart syndrome, 179, 183
lung, surfactant replacement in, 705-706
- Transposition of great arteries, 124-126
diagnosis of, 167
fetal circulation in, 14
hypoxemia in, management of, 126
pathophysiology of, 124-126
radiography of, 81-84
surgery for, 166-173
goal of, 168
in Taussig-Bing anomaly, 170
neurodevelopmental outcome of, 241-244
physiologic considerations in, 167
results of, 170-173
timing of, 167-168
with aortic arch obstruction, 170
with intact ventricular septum in older neonate, 168-170
- Trauma, lung, in mechanical ventilation. *See* Volutrauma.
- Tretinoin, fetal cardiovascular effects of, 56-57
- Tricuspid valve, stenosis of, balloon valvotomy for, 147-148
- Triple screen, in second trimester, 292-296
- Trisomy 13, congenital heart disease in, 112
- Trisomy 18
congenital heart disease in, 112
fetal loss in, 334
screening for, 296
- Trisomy 21. *See* Down syndrome.
- Turner's syndrome, congenital heart disease in, 112
- Twin(s)
preterm premature rupture of membranes with, 726, 775-776
ultrasound of, 345, 348
- Twin-twin transfusion syndrome, circulation abnormalities in, 21, 23
- Tyrosinemia, screening for, 456-457
- Ultrasound
failure to diagnose abnormality in, legal aspects of, 469-471
for Down syndrome screening, 303-319
abdomen, 309-312
anatomic score in, 314-315
chest, 307-309
extremities, 312-313
first-trimester, 333-352
head and neck, 304-307, 327-328. *See also* Nuchal translucency.

- Ultrasound (*Continued*)
 for neural tube defect screening, 282-286
 Umbilical artery, anomalies of, in Down syndrome, 311-312
 Umbilical cord
 compression of, in preterm premature rupture of membranes, 765-766, 840-841
 prolapse of, in preterm premature rupture of membranes, 765-766
Ureaplasma urealyticum, in intra-amniotic infections, 739
- VACTERL association, congenital heart disease in, 113
 Vaginal bleeding, preterm premature rupture of membranes and, 725
 Vaginosis, bacterial, preterm premature rupture of membranes in, 728
 Valvotomy, balloon, for congenital heart disease, 138, 141-148
 Vas deferens, absence or atresia of, in cystic fibrosis, 386-387
 Vasodilators, for persistent pulmonary hypertension, 618
 Velocardiofacial syndrome, congenital heart disease in, 4-6, 112
 Ventilation. *See also* Mechanical ventilation.
 liquid, versus extracorporeal membrane oxygenation, 637-638
 Ventricle(s)
 hypoplasia of, fetal circulation in, 14-15
 single, 128-132
 anatomy of, 128-129
 physiology of, 130
 surgery for, neurodevelopmental outcome of, 243
 treatment of, 130-132
 Ventricular premature beats, neonatal, 199
 Ventricular tachycardia
 fetal, 188-189, 191-192
 neonatal, 199-201
 Ventriculomegaly, in Down syndrome, 307
 Verapamil, for arrhythmias, neonatal, 203
 Vitamin A and derivatives, fetal cardiovascular effects of, 56-57
 Vitamin C deficiency, preterm premature rupture of membranes in, 724
 Volume, in pulmonary graphics, 488-489
 Volume-assured pressure support ventilation, 553-554
 Volume-controlled ventilation, 547-560
 advantages of, 548-549
 assist-control. *See* Assist-control ventilation.
 clinical considerations in, 557-559
 description of, 547-548
 design of, 549-552
 future of, 559
 intermittent mandatory ventilation. *See* Intermittent mandatory ventilation.
 nomenclature of, 549
 operation of, 549-552
 pressure-limited ventilation with, 553-557
 pressure-regulated, 554-556
 synchronous intermittent mandatory ventilation. *See* Synchronous intermittent mandatory ventilation.
 versus pressure-controlled ventilation, 549-552
 volume-assured pressure support, 553-554
 volume-guaranteed pressure-limited, 556-559
 Volume-guaranteed pressure-limited ventilation, 556-559
 Volutrauma, 505-515
 atelectotrauma with, 508-510
 definition of, 505-506
 distal organ effects of, 508
 hypocapnia in, 521
 mechanisms of, 506-508
 prevention of, 510-512
 structural aspects of, 506-507
- Waveform graphics, pulmonary. *See* Pulmonary graphics.
 Weaning, from high-frequency ventilation, 598-599, 602-603
 Weight, maternal, preterm premature rupture of membranes and, 724-725
 White blood cell count, in intra-amniotic infections, 740
 Wide complex tachycardia, neonatal, 200
 Williams syndrome, congenital heart disease in, 112
 Wolff-Parkinson-White syndrome, 194
 Wung strategy, for mechanical ventilation, in persistent pulmonary hypertension, 524, 616-617
- Zinc deficiency, preterm premature rupture of membranes in, 724

